Edwards Lifesciences Corporation (NYSE:EW) Director Schack Wesley W. Von sold 1,000 shares of the business’s stock in a transaction on Thursday, November 9th. The shares were sold at an average price of $104.15, for a total value of $104,150.00. Following the completion of the sale, the director now directly owns 2,622 shares in the company, valued at approximately $273,081.30. The sale was disclosed in a legal filing with the SEC, which is available through this link.

Edwards Lifesciences Corporation (EW) traded down $0.93 during midday trading on Monday, reaching $103.85. The company had a trading volume of 1,728,200 shares, compared to its average volume of 1,650,290. Edwards Lifesciences Corporation has a fifty-two week low of $81.12 and a fifty-two week high of $121.45. The company has a quick ratio of 2.76, a current ratio of 3.49 and a debt-to-equity ratio of 0.33. The company has a market capitalization of $22,270.00, a P/E ratio of 28.77, a PEG ratio of 1.86 and a beta of 0.46.

Edwards Lifesciences Corporation (NYSE:EW) last posted its earnings results on Tuesday, October 24th. The medical research company reported $0.84 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.86 by ($0.02). Edwards Lifesciences Corporation had a net margin of 22.47% and a return on equity of 27.22%. The business had revenue of $821.50 million during the quarter, compared to analyst estimates of $833.85 million. During the same period in the previous year, the firm posted $0.68 earnings per share. The firm’s revenue was up 11.1% on a year-over-year basis. equities research analysts predict that Edwards Lifesciences Corporation will post 3.75 EPS for the current year.

TRADEMARK VIOLATION WARNING: This report was first published by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this report on another website, it was illegally stolen and reposted in violation of United States and international trademark and copyright laws. The legal version of this report can be read at https://www.thecerbatgem.com/2017/11/13/edwards-lifesciences-corporation-ew-director-schack-wesley-w-von-sells-1000-shares.html.

A number of large investors have recently bought and sold shares of EW. Victory Capital Management Inc. boosted its position in shares of Edwards Lifesciences Corporation by 4.6% during the third quarter. Victory Capital Management Inc. now owns 557,773 shares of the medical research company’s stock worth $60,969,000 after buying an additional 24,399 shares during the period. Korea Investment CORP boosted its position in shares of Edwards Lifesciences Corporation by 144.5% during the third quarter. Korea Investment CORP now owns 355,683 shares of the medical research company’s stock worth $38,880,000 after buying an additional 210,200 shares during the period. Raymond James Financial Services Advisors Inc. boosted its position in shares of Edwards Lifesciences Corporation by 53.3% during the second quarter. Raymond James Financial Services Advisors Inc. now owns 11,991 shares of the medical research company’s stock worth $1,418,000 after buying an additional 4,170 shares during the period. Westpac Banking Corp boosted its position in shares of Edwards Lifesciences Corporation by 13.5% during the second quarter. Westpac Banking Corp now owns 14,214 shares of the medical research company’s stock worth $1,681,000 after buying an additional 1,691 shares during the period. Finally, Principal Financial Group Inc. boosted its position in shares of Edwards Lifesciences Corporation by 41.9% during the second quarter. Principal Financial Group Inc. now owns 465,885 shares of the medical research company’s stock worth $55,086,000 after buying an additional 137,643 shares during the period. 82.17% of the stock is owned by hedge funds and other institutional investors.

EW has been the subject of several research analyst reports. Bank of America Corporation lifted their price objective on Edwards Lifesciences Corporation from $140.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, July 27th. BidaskClub downgraded Edwards Lifesciences Corporation from a “strong-buy” rating to a “buy” rating in a research report on Wednesday, July 19th. SunTrust Banks, Inc. lifted their price objective on Edwards Lifesciences Corporation to $14.00 and gave the company a “buy” rating in a research report on Monday, July 17th. Canaccord Genuity reiterated a “buy” rating and issued a $155.00 price objective (up previously from $150.00) on shares of Edwards Lifesciences Corporation in a research report on Sunday, July 30th. Finally, William Blair reiterated an “outperform” rating on shares of Edwards Lifesciences Corporation in a research report on Monday, August 28th. Seven research analysts have rated the stock with a hold rating, sixteen have given a buy rating and one has given a strong buy rating to the stock. The company has an average rating of “Buy” and an average price target of $125.17.

About Edwards Lifesciences Corporation

Edwards Lifesciences Corporation is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company is engaged in patient-focused innovations for structural heart disease and critical care monitoring. Its segments include United States, Europe, Japan and Rest of World.

Insider Buying and Selling by Quarter for Edwards Lifesciences Corporation (NYSE:EW)

Receive News & Stock Ratings for Edwards Lifesciences Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Edwards Lifesciences Corporation and related stocks with our FREE daily email newsletter.